Oncolytics Biotech Inc. Common Stock (ONCY)

FairStock Score: 10/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with the numbers, because a biotech story without revenue must earn trust through science and capital, and here the figures are unforgiving. Oncolytics reports no revenue in any filed period I see. In fiscal 2025, the year ended 2025-12-31, net income was -$28.8 million, worse than -$22.8 million in fiscal 2024, the year ended 2024-12-31. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$9.4 million versus -$5.3 million in fiscal Q2 2025, the quarter ended 2025-06-30. Fiscal Q1 2026, the quarter ended 2026-03-31, showed -$9.2 million versus -$4.7 million in fiscal Q1 2025, the quarter ended 2025-03-31. Diluted EPS was -$0.08 in both fiscal Q2 2026 and fiscal Q1 2026, and -$0.30 in fiscal 2025. At the close on 2026-10-13, the price was $0.49 and market cap $62.5M. FairStock calculations show P/E -1.40, P/B 1349.35, ROCE -211.24%, and a FairStock Score of 10/100. The Lynch category is none because only two years of filed results are available and three are needed. The business has a clinical pipeline and a Roche supply agreement, but no approved product, no pricing power, and no commercial moat. Growth today means growing losses, not revenue. Graham would ask for a margin of safety in earnings or assets; here the P/B shows almost no asset support and P/E is negative. This is a binary clinical-stage option, not a proven compounding business.

In plain English: Oncolytics Biotech is a tiny clinical-stage drug developer testing an immunotherapy called pelareorep in several cancer types. It has no reported revenue, and its losses have been growing: in fiscal 2025, the year ended 2025-12-31, it lost $28.8 million, and in fiscal Q2 2026, the quarter ended 2026-06-30, it lost $9.4 million. The stock price is very low in dollar terms, but because there are no profits and almost no accounting value of net assets backing the shares, it does not look cheap on the numbers; it looks like a speculative bet on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer